Gut microbiota mediate vascular dysfunction in a murine model of sleep apnoea: effect of probiotics

Eur Respir J. 2023 Jan 19;61(1):2200002. doi: 10.1183/13993003.00002-2022. Print 2023 Jan.

Abstract

Background: Obstructive sleep apnoea (OSA) is a chronic prevalent condition characterised by intermittent hypoxia (IH), and is associated with endothelial dysfunction and coronary artery disease (CAD). OSA can induce major changes in gut microbiome diversity and composition, which in turn may induce the emergence of OSA-associated morbidities. However, the causal effects of IH-induced gut microbiome changes on the vasculature remain unexplored. Our objective was to assess if vascular dysfunction induced by IH is mediated through gut microbiome changes.

Methods: Faecal microbiota transplantation (FMT) was conducted on C57BL/6J naïve mice for 6 weeks to receive either IH or room air (RA) faecal slurry with or without probiotics (VSL#3). In addition to 16S rRNA amplicon sequencing of their gut microbiome, FMT recipients underwent arterial blood pressure and coronary artery and aorta function testing, and their trimethylamine N-oxide (TMAO) and plasma acetate levels were determined. Finally, C57BL/6J mice were exposed to IH, IH treated with VSL#3 or RA for 6 weeks, and arterial blood pressure and coronary artery function assessed.

Results: Gut microbiome taxonomic profiles correctly segregated IH from RA in FMT mice and the normalising effect of probiotics emerged. Furthermore, IH-FMT mice exhibited increased arterial blood pressure and TMAO levels, and impairments in aortic and coronary artery function (p<0.05) that were abrogated by probiotic administration. Lastly, treatment with VSL#3 under IH conditions did not attenuate elevations in arterial blood pressure or CAD.

Conclusions: Gut microbiome alterations induced by chronic IH underlie, at least partially, the typical cardiovascular disturbances of sleep apnoea and can be mitigated by concurrent administration of probiotics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Coronary Artery Disease* / complications
  • Coronary Artery Disease* / therapy
  • Disease Models, Animal
  • Gastrointestinal Microbiome* / physiology
  • Hypoxia
  • Mice
  • Mice, Inbred C57BL
  • Probiotics*
  • RNA, Ribosomal, 16S
  • Sleep Apnea, Obstructive* / complications
  • Sleep Apnea, Obstructive* / therapy

Substances

  • trimethyloxamine
  • RNA, Ribosomal, 16S